Rove MagicCorner

investor Ocugen (OCGN)

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

[Ocugen @Ocugen]

Ocugen will be at #BIO2026 in San Diego!

Abhi Gupta, EVP, Commercial & Business Development, will be speaking at the BIO Int'l Convention as we continue advancing our mission to enable global access for patient through effective partnerships. @IAmBiotech #Biotech #GeneTherapy

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇
Insiders are purchasing $OCGN shares is always a good sign!!!
Zhang has exercised his options to purchase, by paying $1.42 per share.

Russell 3000 imo is the start of the leg up!

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN #insider
CFO Johnson Greene acquires 21,300 shares at $1.23, 300 of which belong to her husband 😅
#LETSGOOO

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

Guidance for the industry has been issued in May 2026.
Just in time for us ..... lmao!!!

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN #centralizedprocedure
Gene therapies legally belong to the category of Advanced Therapy Medicinal Products (ATMPs), a group of innovative drugs for which this procedure is strictly mandatory in the European Union
https://t.co/i6J6Y8A6cu

#LETSGOOO

[Ocugen @Ocugen]

“I have more adaptation to light and darkness.” – Nancy

After living with #retinitispigmentosa for 31 years, Nancy shares her story and hope for the future after participating in Ocugen’s #OCU400 clinical trial. #Ocugen $OCGN

Learn more about OCU400: https://t.co/OXzETxjDpJ

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN @MHRAgovuk
It's official!! The medical community now knows about this part of the complete clinical trial:
1. Recruitment.
2. Follow-up phase.
3. Final results.
#LETSGOOO
https://t.co/99LlOuoA4H

[TheUrbanFarmer @NattaCop]

$OCGN people will see participants of the trial and early access program give testimony of their happiness, experience, gratitude and express just how much their quality of life has improved after treatment. They’ll also see the countless people desperately waiting and praying for approval. Then they’ll ask themselves how tf is it possible that our price is where it’s at.

The way I see it is the market tends to discount companies until the data makes value undeniable. If you look at CELC chart, there were probably tons of signs and retailers saying this should be worth more, but the market continued to discount then until the data released and made value undeniable.

It’s hard to describe the value that our drugs bring to people and the size of these underserved markets we’ll basically have to ourselves. When data drops and our value becomes undeniable it will a sight people won’t forget.

Imo this is the catalyst that rules them all, we could see a partnership or rolling BLA bring price up above $5 or even more but really it’s nothing compared to when fair value gets recognized. 🍻

[Rove MagicCorner @RMagiccorner]

https://t.co/0nZYuG04ak

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN 👇 👇 👇

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN Approved names for the initial marketing of two of the three gene therapies; we've gone from scientific to commercial names.😎
¿Lotes de OCU400 LISTOS?🧐🤔🤫
#LETSGOOO
FYSTARZI= #OCU410ST
LYTSTARIQ= #OCU400

[Rove MagicCorner @RMagiccorner]

https://t.co/QFLzE1ipfd

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN #OCU410

ONE TIME TREATMENT!!!

[Rove MagicCorner @RMagiccorner]

https://t.co/fTwJp4mA5u

[TheUrbanFarmer @NattaCop]

$OCGN one approval validates the platform’s road map, it no longer starts from zero. FDA will have already seen the delivery method, safety profile, manufacturing package, endpoint logic, and clinical design. That creates a regulatory blueprint for the many follow up drugs to come that are built on the same modifier gene therapy platform. This company is going to have back to back to back BLA’s for many years to come. 🍻

[Rove MagicCorner @RMagiccorner]

https://t.co/zlJuk3tqOl

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen 👇 ♥️

https://t.co/pqGgHiDKHj

[Supplements Manufacturer @MoreFlax]

$OCGN #OCUGEN @Ocugen @drsmusunuri 👏👏👏👏

Market, soon will realize the potential of this ground braking technology.
Just think, if Ocugen's FDA acceptable endpoints becomes industry standards...

Ocugen’s modifier gene therapies (e.g., #OCU400 for retinitis pigmentosa, #OCU410 for geographic atrophy/dry AMD, #OCU410ST for Stargardt) use endpoints that the FDA has explicitly accepted or aligned on for their trials. These reflect evolving FDA thinking on retinal/gene therapy trials.

Ocugen is successfully navigating and contributing to the evolving framework.

Ocugen’s achievements (FDA alignment on Phase 3 designs, RMAT/ODD designations, adaptive trials) show their endpoints are fit-for-purpose and regulatorily viable, especially for rare/orphan indications where flexibility exists.

[AWAREOFSILENCE @AWAREOFSILENCE]

#OCUGEN REMINDS Why phase three of #OCU400 could set the new standard for gene-agnostic therapy going forward,but far beyond, the direction is unstoppable @US_FDA @EMA_News #RP #OPHTHALMOLOGY
#LETSGOOO
https://t.co/FZZAUxSIv7